Oak Hill Bio is set to reach the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III, a move aimed at funding an investigational rare disease candidate that Roche shelved. RA Capital’s structure combines a SPAC pathway with PIPE funding, positioning Oak Hill to compete in an Angelman syndrome landscape already populated by Phase 3 programs. The financing storyline signals continuing appetite for late-preclinical to early clinical rare disease assets that can potentially be differentiated from existing approaches. Oak Hill’s entry route also highlights how investors are using blank-check vehicles to fund targeted neurodevelopmental development when traditional timelines remain uncertain.